COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial
Why the study?
No drug has been proven efficacious to prevent the post-pericardiotomy syndrome (PPS), although colchicine appears safe and effective for pericarditis treatment and prevention.
Does colchicine prevent post-pericardiotomy syndrome in patients following cardiac surgery?
Population
360 patients following cardiac surgery (mean age 65.7 ± 12.3 years, 66% males)
Comparison
Colchicine vs placebo starting on the third post-operative day
Design
Multicentre, randomized, double-blind, placebo-controlled trial
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Supports colchicine for PPS prevention after cardiac surgery; confirms efficacy in a dedicated RCT.
Structured PICO
Does colchicine prevent post-pericardiotomy syndrome in patients following cardiac surgery?
P
Population
360 patients following cardiac surgery (mean age 65.7 ± 12.3 years, 66% males)
I
Intervention
Colchicine started on the third post-operative day (1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose)
C
Comparator
Placebo
O
Outcome
Incidence of post-pericardiotomy syndrome (PPS) at 12 months
Colchicine safely and effectively reduces the risk of developing post-pericardiotomy syndrome and its related complications following cardiac surgery.
Cite This Study
Imazio et al. (2010) studied this question.